Project
A single-arm phase II trial of the addition of niraparib to anti-PD-L1 antibody maintenance in patients with SLFN11-positive, extensive-disease small cell lung cancer.
Ongoing - recruitment active · 2023 until 2027
Quinter Janine, Radovanovic Suzana, Jörger Markus
Type
Clinical Studies
Range
Multicentric, KSSG as main centre
Units
Status
Ongoing - recruitment active
Start Date
2023
End Date
2027
Financing
Industry
Labels
lung cancer